INFORMATION DISCLOSURE CITATION					ATTY, DOCKET NO. PC10664A				SERIAL NO. 09/451,641						
(Use several sheets if necessary)					APPLICANT Danchen Gao, et al.				o, et al.	γ					
					***********	FILING DATE November 30, 1999				GROUP 1618					
							. PATEN	T DOC	JMENTS	1			r	,	
EXAMINER INITIAL	ER DOCUMENT NUMBI		:R		DATE NAME		CLASS	SUBCLASS	FILING IF APPR	DAYF OPRIAT					
	us	5	5	6	3	1	6	5	10/8/96	Talley, et al	.	514	406		
	us	6	2	3	2	4	2	2	5/15/01	Spitz, et al.	-	526	351	-	
											\dashv				
											\dashv				
															
					Er	2001	CNDAT	CNT DO	CUMEN'	re					
					•••••	JKE1	GNFAI	ENIDO	COMEN	10	Т			Ι	
		DOCUMENT NUMBER						DATE	COUNTRY		CLASS	SUBCLASS	TRANS	LATION	
	EP	0	4	8	8	8	5	6	9/27/95	Europe (English langui equivalent US No. 6,232,422 (above)	Pat	C01F	5/30	YES	X
	wo	0	0	4	8	5	8	3	8/24/00	Internationa		A61P	25/06		
											_				
	\dashv	***************************************													-
				<u> </u>			1		<u> </u>						<u> </u>
		T	ОІН	EK DOC	UMENIS	s (Inc	luaing A	utnor, i	itie, Date,	Pertinent Pag	70S, E	tc.)		0000000 0000	
	-	Vane, "Towards a better Aspirin", Nature, Vol. 367, pp. 215-216 (1994)													
		Battistini, et al., "COX-1 and COX-2: Toward the Development of More Selective NSAIDs", Drug News and Perspectives, Vol. 7, pp. 501-512 (1994)													
	-	Statutory Declaration of Professor Ian Tucker, dated January 4, 2003													
	+	Römpp Cemie Lexikon, 9. Auflage, Band 3, Georg Thieme Verlag, Stuttgart, 1990; pp. 2368-2370													
	_	Teng, et al., "Formulation dependent pharmacokinetics, bioavailability and renal toxicity of a selective cyclooxygenase-1 inhibitor sc-560 in the rat", <i>J. Pharm. Pharmaceut. Sci.</i> (www.ualberta.ca/~csps), Vol. 6(2); pp. 205-210 (2003)													
	\perp	Strickley, "Solubilizing Excipients in Oral and Injectable Formulations", Pharmaceutical Research, Vol. 21(2), pp. 201-230 (2004)													

INFORMATION DISCLOSURE CITATIO	N ATTY, DOCKET NO. PC10664A	SERIAL NO. 09/451,641				
(Use several sheets if necessary)	APPLICANT Danchen Gao, et al.	SERIAL NO. 09/451,041				
(Ose several sheets if hecessary)		CDOUD 1619				
	FILING DATE November 30, 1999	GROUP 1618				
Waterbeemd, et al., "Estimation	Waterbeemd, et al., "Estimation of Solubility, Permeability, Absorption and Bioavailability", Drug Bioavailability, Vol. 8, pp. 207-209					
Davies, et al., "Clinical Pharmaco Pharmacokinet, Vol. 39(3); pp. 2	Davies, et al., "Clinical Pharmacokinetics and Pharmacodynamics of Celecoxib – A selective Cyclo-Coxygenase-2 Inhibitor", Cl. Pharmacokinet, Vol. 39(3); pp. 225-242 (2000)					
Barnett International's Strategies Automating Solubility, June 2 4	Barnett International's Strategies for Improving Solubility, Practical Applications for Examining, Measuring, Predicting and Automating Solubility, June 2 – 4, 2004, Airport Marriott, Philadelphia, PA (6 pages) 2004 PSG Technical Conference, Current Pharmaceutical Products, What Was Once Novel is Now Standard, Le Jardin, 8440 Highway 27, Woodbridge, Ontario October 26 – 27, 2004 (8 pages) Memet Bahar, Experimental Protocol – Crystallization Experiments, Product: Celecoxib; Preparation Date: 03.09-3.09.2004 (5 pages) Davies, et al., "Celecoxib: a new option in the treatment of arthropathies and familial adenomatous polyposis", Expert Opinion on Pharmacotherapy, Vol. 2(1); pp. 139-152 (2001) Declaration of Neal M. Davies dated November 17, 2004					
Declaration of Neal M. Davies da						
Declaration of Dr. Tambay Taski	Deciaration of Dr. Tambay Taskin dated February 8, 2006 Kesten, "Control and Optimisation of Cement Quality with Laser Diffraction Particle Size Analysis and Dry Dispersion, Sympatec GmbH, D-38678 Clausthal-Zellerfeld, Germany (1997) Clinical Trial Protocol N49-95-02-006, dated September 6, 1995 Internal redacted Pfizer document dated July 26, 2007 re: particle size analysis of Arti X 200 mg tablets Consultant Agreement re: Clinical Trial N49-95-02-006 dated September 20, 1995 Barber, et al., "A Logical Stepwise Approach to Laser Diffraction Particle Size Distribution Analysis Methods Development and Validation", "Pharmaceutical Development and Technology, Vol. 3(2); pp. 153-161 (1998) Pharmaceutical Dosage Forms: Tablets, 2 rd Edition, Vol. 2, (1990)					
Kesten, "Control and Optimisatio GmbH, D-38678 Clausthal-Zellei						
Clinical Trial Protocol N49-95-02						
Internal redacted Pfizer documer						
Consultant Agreement re: Clinica						
Barber, et al., "A Logical Stepwis Validation", Pharmaceutical Deve						
Pharmaceutical Dosage Forms:						
Jennings, et al., "Particle size me	asurement: the equivalent spherical diameter", Proc.	. R. Soc. Lond. A, Vol. 419, pp. 137-149 (1988)				
United States Provisional Patent	Application No. 60/047,535, filed May 22, 1997.					
Affidavit of Professor Shimon Be Products Maabarot Ltd. in Israel	Affidavit of Professor Shimon Benita, filed in support of the Opposition of Teva Pharmaceuticals, Ltd. And Tri- Products Maabarot Ltd. in Israel (date unknown)					
Affidavit of Professor Shimon Bei Mr. Goren, filed in Israeli oppositi	ita in response to Affidavits submitted by G.D. Searl on (date unknown)	le & Co. by Professor Jurgensen, Dr. Davis and				
Opposition by the Pharmaceutica	Industry Chamber of Bolivia dated October, 2000 (i	English translation)				
Rejection by Republic of Colomb	a dated March 16, 2005 (English translation)					
Rejection by Costa Rica dated an	prox. 2008, later overcome. (English translation)					
Affidavit of Dr. Cynthia Webb filed opposition (date unknown)	on behalf of Teva Pharmaceutical Industries Ltd. Ar	nd Trima Israeli Medival Products Ltd. In Israeli				
Affidavit of Professor Avraham Di In Israeli opposition (date unknow	non filed on behalf of Teva Pharmaceutical Industri n)	ies Ltd. And Trima Israeli Medival Products Ltd.				
Affidavit of Professor Avraham Di and Mr. Goren, filed in Israeli opp	non in response to Affidavits submitted by G.D. Sea osition (date unknown)	arle & Co. by Professor Jurgensen, Dr. Davis				

		T T				
INFORM	IATION DISCLOSURE CITATION	ATTY. DOCKET NO. PC10664A	SERIAL NO. 09/4	51,641		
(Use	e several sheets if necessary)	APPLICANT Danchen Gao, et al.				
		FILING DATE November 30, 1999	GROUP 1618	3		
	Opposition filed by Association of Ph	armaceutical Laboratories in Ecuador dated Augus	t, 2000 (English Translation)			
	Decision by European Patent Office	n Appeal No. T0696/05-3302 dated February 5, 2009				
	Opposition decision by European Pa	tent Office regarding European Patent No. EP1049	467 dated March 30, 2005			
	Notice of Opposition by Teva Pharmaceutical Industries Ltd. and supporting documents dated July 8, 2003 regarding Europei Patent No. EP1049467 Opposition by Zentiva, k.s in Estonia dated February 17, 2010 regarding Patent No. EE 04834 Oposition by Fako Ltd. in Eurasia regarding Eurasian Patent No. 3363 (English translation) Affidavit of Neal M. Davies, Ph.D. dated March 2006, regarding Guatemalan Patent Application No. PI-990203 and US5,563,					
	Final Decision filed in Guatemala ordering the Registry of Intellectual Property to proceed with respective registry region 2003					
	Rejection filed regarding Application	No. PI-990203 in Guatemala dated June 16, 2003				
	Administrative Appeal Brief regarding Application No. PI-990203 in response to the Guatemalan Examiner's rejection of Ju 2003 Submission in Guatemala dated April, 2004 Israel opposition summations, July 2006 (English translation)					
	Opposition Decision by Israel Patent Office dated February 28, 2008 (English translation) Appeal to Set Aside Refusal of Application and Reconsideration to Grant Patent to Philippine AN:1-1999-02951 dated					
	Notice of Appeal by Teva Pharmaceutical Industries Ltd. and Trima Israeli Medical Products Maabarot Ltd., filed in Israel, June 5, 2009 (English translation)					
	Declaration by Neal M. Davies, Ph.D.	osition				
	Response to Statement filed by the C No. 1999-002453	amara de le Industria Farmaceutica, in Venezuela	regarding Venezuelan Patent A	Application		
	Annulment Action filed in Peru on Jar	nuary 11, 2010				
	Appeal filed by Polpharma in Poland	regarding Polish Patent No. Pt. 200957 BI (English	Translation)			
	Appeal filed by Zentiva in Poland reg	arding the granting of Patent No.PL 200957 (Engli	sh Translation)			
	Decision of Industrial Property Office (English translation)	of the Slovak Republic dated April 26, 2010 regard	ling Slovak Republic Patent No.	. SK 283510		
	Nullity Action filed by Zentiva in Slova	ık Republic on July 19, 2008 (English translation)				
	Opposition arguments by Teva Pharm	naceuticals in Israel (date unknown) (English trans	lation)			
	Turkish opposition summary by Fako	llaclari A.S. (June 18, 2001) (English translation)				
	Turkish opposition by Professor. Leve	ent Öner dated June 5, 2001 (English translation)				

INFORMATI	ION DISCLOSURE CITATION	ATTY, DOCKET NO. PC10664A	SERIAL NO.	09/451,641				
(Use se	everal sheets if necessary)	APPLICANT Danchen Gao, et al.						
		FILING DATE November 30, 1999	GROUP	1618				
	Turkish opposition by Nobel Ilac Sanayi Ve Ticaret, A.S. dated June 19, 2001 (English translation)							
	Turkish opposition statement by Fako Ilaclari dated June 18, 2001 (English translation)							
EXAMINER	EXAMINER DATE CONSIDERED							
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE